BR112023001734A2 - Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação - Google Patents

Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação

Info

Publication number
BR112023001734A2
BR112023001734A2 BR112023001734A BR112023001734A BR112023001734A2 BR 112023001734 A2 BR112023001734 A2 BR 112023001734A2 BR 112023001734 A BR112023001734 A BR 112023001734A BR 112023001734 A BR112023001734 A BR 112023001734A BR 112023001734 A2 BR112023001734 A2 BR 112023001734A2
Authority
BR
Brazil
Prior art keywords
formulations
articles
manufacture
methods
autoinjectors
Prior art date
Application number
BR112023001734A
Other languages
English (en)
Inventor
Pulley Jennifer
Tao Tang Meina
Tole Swati
Tyrrell Helen
Abouhossein Mariam
Amarchinta Hemanth
Boruvka Audrey
Ting Ding Han
L Flores Heather
Scott Giese Glen
Ravanello Renato
Zhang Wenhui
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of BR112023001734A2 publication Critical patent/BR112023001734A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÕES, ARTIGOS DE FABRICAÇÃO, AUTOINJETORES E MÉTODOS PARA TRATAR UM DISTÚRBIO INFLAMATÓRIO GASTROINTESTINAL EM UM INDIVÍDUO E PARA ADMINISTRAR POR VIA SUBCUTÂNEA UMA FORMULAÇÃO. São fornecidas formulações compreendendo um anticorpo anti-integrina beta7 ou um fragmento de ligação ao antígeno do mesmo, incluindo formulações farmacêuticas. Também são fornecidos artigos de fabricação compreendendo tais formulações e métodos de uso de tais formulações.
BR112023001734A 2020-07-31 2021-07-29 Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação BR112023001734A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063059427P 2020-07-31 2020-07-31
PCT/US2021/043690 WO2022026699A1 (en) 2020-07-31 2021-07-29 Anti-integrin beta7 antibody formulations and devices

Publications (1)

Publication Number Publication Date
BR112023001734A2 true BR112023001734A2 (pt) 2023-02-28

Family

ID=77693570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001734A BR112023001734A2 (pt) 2020-07-31 2021-07-29 Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação

Country Status (11)

Country Link
EP (1) EP4188958A1 (pt)
JP (1) JP2023536158A (pt)
KR (1) KR20230041071A (pt)
AR (1) AR123085A1 (pt)
AU (1) AU2021316017A1 (pt)
BR (1) BR112023001734A2 (pt)
CA (1) CA3190109A1 (pt)
IL (1) IL300133A (pt)
MX (1) MX2023001157A (pt)
TW (1) TW202222832A (pt)
WO (1) WO2022026699A1 (pt)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
DK2990422T3 (en) 2004-09-03 2018-09-17 Genentech Inc HUMANIZED ANTI-BETA7 ANTAGONISTS AND APPLICATIONS THEREOF
DK2279004T3 (en) 2008-05-16 2015-02-02 Hoffmann La Roche USE OF biomarkers for assessment of treatment of gastrointestinal inflammatory disorders WITH beta7 integrin antagonists
JP2012519706A (ja) 2009-03-06 2012-08-30 ジェネンテック， インコーポレイテッド 抗体製剤
PT2704742T (pt) * 2011-05-02 2017-11-15 Millennium Pharm Inc Formulação de um anticorpo anti-a47
CN103732275B (zh) 2011-06-17 2016-08-17 Shl集团有限责任公司 注射设备
CA2839496C (en) 2011-06-17 2016-02-09 Shl Group Ab Injection device
EP3933401A3 (en) 2013-03-27 2022-04-13 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP3122377A4 (en) 2014-03-27 2018-03-14 F.Hoffmann-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
AR103782A1 (es) * 2015-02-26 2017-05-31 Genentech Inc ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
US20230033021A1 (en) * 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Also Published As

Publication number Publication date
MX2023001157A (es) 2023-02-22
WO2022026699A1 (en) 2022-02-03
AR123085A1 (es) 2022-10-26
AU2021316017A1 (en) 2023-02-16
IL300133A (en) 2023-03-01
JP2023536158A (ja) 2023-08-23
EP4188958A1 (en) 2023-06-07
KR20230041071A (ko) 2023-03-23
TW202222832A (zh) 2022-06-16
CA3190109A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
CY1123586T1 (el) Υποδορια σκευασματα αντισωματος her2
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
BR112019022972A2 (pt) Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
BR112014021101A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
BR112016026811A2 (pt) formulação de anticorpo
SI2691112T1 (en) STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
MX2024008464A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
JOP20220030A1 (ar) صيغ مضادة لـ c5 عالية التركيز
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112022012514A2 (pt) Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
BR112022011228A2 (pt) Formulação farmacêutica líquida, artigo de fabricação, kit e método para tratar uma doença ou distúrbio em um indivíduo
EP3541943A4 (en) MICRO-ORGANISM FOR ADMINISTERING A MEDICINAL PRODUCT FOR THE TREATMENT OF A GASTROINTESTINAL DISEASE, WHICH EXPRESSES AND SECRETS P8 PROTEIN, AND PHARMACEUTICAL COMPOSITION CONSISTING OF THIS MICRO-ORGANISM FOR THE PREVENTION OR TREATMENT OF A GASTROINTESTINAL DISEASE
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112021021210A2 (pt) Conjunto de polipeptídeos, método para gerar um polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico, segundo polipeptídeo precursor heterodimérico e composição farmacêutica
BR112023020622A2 (pt) Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
MX2023015070A (es) Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]